EVO

Handel nachbörslich: 5.55

Evotec Se Adr (EVO)

Überblick Nachrichten Preisverlauf Warum fällt EVO? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Evotec Se Adr Stock (EVO) Company Profile

Evotec Se Adr

Healthcare (1196)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

EVO's Discussions on Twitter

Vergleichen Sie EVO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EVO	5.55	2.00B	853.32M	-184.46M	-264.08M	-0.3415
ZTS	176.42	79.51B	9.15B	2.43B	2.31B	4.92
TAK	13.53	42.89B	30.27B	1.93B	3.45B	0.444
HLN	9.43	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.49	18.51B	16.77B	-959.00M	1.37B	-2.00
VTRS	13.00	15.37B	15.24B	-646.50M	1.88B	1.53

Evotec Se Adr Stock (EVO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-01-18	Hochstufung	RBC Capital Mkts	Sector Perform → Outperform
2023-06-23	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2023-06-16	Herabstufung	BofA Securities	Buy → Neutral
2023-06-08	Hochstufung	Citigroup	Neutral → Buy
2023-04-04	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-12-09	Eingeleitet	H.C. Wainwright	Buy
2022-11-16	Herabstufung	Deutsche Bank	Buy → Hold
2022-08-10	Herabstufung	Morgan Stanley	Overweight → Underweight
2022-03-02	Fortgesetzt	Cowen	Outperform
2022-01-07	Fortgesetzt	Citigroup	Neutral

Alle ansehen

Evotec Se Adr Aktie (EVO) Neueste Nachrichten

Finanzdaten der Evotec Se Adr-Aktie (EVO)

Evotec Se Adr (EVO)

Evotec Se Adr Stock (EVO) Company Profile

Vergleichen Sie EVO mit anderen Aktien

Evotec Se Adr Stock (EVO) Upgrades & Downgrades

Evotec Se Adr Aktie (EVO) Neueste Nachrichten

Halozyme outlines plan to acquire Evotec for €2 billion By Investing.com - Investing.com UK

Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid - MSN

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion - AOL

Evotec SE responds to media speculation - Investing.com

Halozyme Therapeutics sinks after confirming $2B Evotec buyout offer - Seeking Alpha

Evotec SE responds to media speculation By Investing.com - Investing.com UK

Halozyme proposes $2 billion acquisition of Evotec - Investing.com India

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal - Benzinga

Earnings call: Evotec SE maintains 2024 outlook amid strategic changes - Investing.com India

Evotec SE ADR earnings beat by $0.02, revenue fell short of estimates - Investing.com

Evotec Reports Strategic Growth Amidst Revenue Challenges - TipRanks

Stock Information - Evotec

Annual General Meeting - Evotec

Investor Relations - Evotec

Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com

Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada

Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths - Yahoo Finance

Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar

Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar

Evotec shares crash 36% on profit warning - Investing.com

Antibody Discovery Market Size Expected to Surge to USD 4.8 - GlobeNewswire Inc.

Evotec stock holds Buy rating with price target from TD Cowen By Investing.com - Investing.com India

Evotec (OTCMKTS:EVTCY) Sets New 52-Week Low at $4.65 - Defense World

Financial Metrics Check: Evotec SE ADR (EVO)'s Ratios for Trailing Twelve Months – DWinneX - The Dwinnex

Healthcare Sector - Morningstar

Ratio Examination: Evotec SE ADR (EVO)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex

Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger - Morningstar

Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com South Africa

Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges By Investing.com - Investing.com

Evotec gains R&D license from Centogene for Gaucher disease - Investing.com India

Closing Bell Recap: Evotec SE ADR (EVO) Ends at 5.23, Reflecting a -31.63 Downturn – DWinneX - The Dwinnex

QT to end this December with hardly a whimper: Barclays By Investing.com - Investing.com

Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher By Benzinga - Investing.com UK

Evotec and Variant Bio partner to develop fibrosis treatments By Investing.com - Investing.com

T. Rowe Price Raises Stake in Evotec SE - TipRanks

Germany stocks mixed at close of trade; DAX down 0.03% By Investing.com - Investing.com

Germany stocks mixed at close of trade; DAX down 0.30% By Investing.com - Investing.com

Evotec: R&D, Customer Growth Not Enough To Offset Headwinds - Seeking Alpha

Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus - The Globe and Mail

Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance

Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq

A Peek Into The Markets: US Stock Futures Rise; J&J Secures Emergency Authorization for Covid-19 Vaccine - Benzinga

Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare ConferenceSlideshow (NASDAQ:EVO) - Seeking Alpha

Together for Medicines That MatterEvotec Website (English) - Evotec

Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA

Finanzdaten der Evotec Se Adr-Aktie (EVO)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie EVO